

## CORRIGENDUM

# Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'

P. Schöffski, A. Wozniak, S. Stacchiotti, P. Rutkowski, J.-Y. Blay, L. H. Lindner, S. J. Strauss, A. Anthony, F. Duffaud, S. Richter, V. Grünwald, M. G. Leahy, P. Reichardt, J. Sufliarsky, W. T. van der Graaf, R. Sciot, M. Debiec-Rychter, T. van Cann, S. Marréaud, M. Lia, T. Raveloarivahy, L. Collette & S. Bauer

*Ann Oncol* 2017; 28: 3000–3008 (doi: 10.1093/annonc/mdx527)

In the original version, one of the authors of the above article was listed incorrectly as 'Paolo Casali' rather than 'Silvia Stacchiotti'. This has now been corrected.